|1||NCT02496208||Recruiting||Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors||
||152||All||18 Years and older (Adult, Older Adult)||NCT02496208||NCI-2014-02379
|July 9, 2015||September 30, 2019||July 14, 2015||August 12, 2019||
|2||NCT03866382||Recruiting||Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors||
||186||All||18 Years and older (Adult, Older Adult)||NCT03866382||NCI-2019-01266
|April 12, 2019||February 28, 2023||February 28, 2023||March 7, 2019||August 13, 2019||
† Study has passed its completion date and status has not been verified in more than two years.